跳至主要内容
临床试验/KCT0002308
KCT0002308撤回未知

Comparison of Topography Guided LASIK with WaveLight EX500 to SMILE with Zeiss VisuMax

Sungmo Eye Hospital of Sekwang Medical Foundation0 个研究点目标入组 450 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
撤回
发起方
入组人数
450

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 o Limit(—)
性别
All

入选标准

  • Below is a list of inclusion criteria. Ocular criteria must be met in both eyes.
  • 1. Subjects upon completion of 19 years of age or older.
  • 2. Able to comprehend and sign an Informed Consent Form.
  • 3. Willing and able to complete all post-surgery visits.
  • 4. Myopia requiring (a) refractive error correction of -0.5 to -8.0 D manifest refraction sphere with
  • (b) astigmatism correction of -0.75 to -5.0 D manifest refraction cylinder and
  • (c) at least 0.75 D of corneal astigmatism.
  • 5. Intended treatment is targeted for emmetropia.
  • 6. Pre-surgery Best-corrected visual acuity of 0 logarithm of the minimum angle of resolution (logMAR) (20/20) or better.
  • 7. Spherical equivalent difference of = 0.5 D between the manifest and cycloplegic refraction outcomes.
  • 8. Spherical equivalent difference of = 0.5 D between refractive error corrections for a minimum of 12 months prior to surgery verified by consecutive refractions and/or medical records or prescription history.
  • 9. For contact lens wearers - Spherical equivalent difference of = 0.5 D between outcomes from consecutive manifest refraction outcomes performed at least 7 days apart after the contact lens wear has been stopped for the appropriate period of time as follows:
  • Soft (extended and daily wear) = 3 days
  • Rigid Gas Permeable (RGP) or Toric = 2 weeks
  • Hard polymethyl methacrylate (PMMA) = 3 weeks

排除标准

  • Below is a list of exclusion criteria. Ocular criteria must not be met in either eye.
  • 1. Pregnancy or lactation, current or planned, during the course of the study.
  • 2. Manifest refraction astigmatism that is more than 1.00 D than the topolyzer astigmatism assessed by Topolyzer Vario.
  • 3. Mixed astigmatism refractive error.
  • 4. Degenerations of structure of the cornea including diagnosed keratoconus, forme fruste kerataconus or pellucid marginal degeneration.
  • 5. Dry eye as identified by the Short questionnaire for dry eye syndrome.
  • 6. A calculated residual stromal bed thickness that is less than 250 µm.
  • 7. History or evidence of active or inactive corneal or other anterior segment disease (e.g, herpes simplex keratitis, recurrent erosion syndrome).
  • 8. Diagnosed advanced glaucoma.
  • 9. Uncontrolled diabetes.
  • 10. Nystagmus or any other condition that would prevent a steady gaze during the treatment.
  • 11. Previous intraocular or corneal surgery.
  • 12. Weakened immune system, including diagnosed collagen vascular, autoimmune or immunodeficiency disease.
  • 13. Systemic medications that may affect corneal healing including, but not limited to steroids, antimetabolites, immune response modifying drugs, etc.
  • 14. Presence or history of any condition or finding that makes the subject unsuitable as a candidate for refractive surgery or study participation or may confound the outcome of the study, in the opinion of the Investigator.
  • 15. Any subject currently participating in another investigational drug or device study that may confound the results of this investigation.
  • 16. A known sensitivity to medications used during the study.

研究者

发起方
Sungmo Eye Hospital of Sekwang Medical Foundation

相似试验